Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies

Letter Medicine, General & Internal

Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease

Gil Y. Melmed et al.

ANNALS OF INTERNAL MEDICINE (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting

Corey A. Siegel et al.

GUT (2021)

添加到收藏夹

Article Cell & Tissue Engineering

Neutralizing antibodies targeting SARS-CoV-2 spike protein

Shi Xiaojie et al.

Summary: Since it was first identified in Wuhan, China at the end of 2019, SARS-CoV-2 causing the worldwide pandemic has dramatically changed people's lives in multiple aspects. Efforts to curb the progression of the pandemic are urgently ongoing, with promising therapeutic antibodies being developed through various approaches. Studies have shown that neutralizing antibodies against SARS-CoV-2 are mainly targeting the RBD and some non-RBD domains, with convergent germline genes identified for effective antibodies.

STEM CELL RESEARCH (2021)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies

Serre-Yu Wong et al.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Nicholas A. Kennedy et al.

Summary: Infliximab treatment in patients with inflammatory bowel disease results in attenuated serological responses to a single dose of the SARS-CoV-2 vaccine. Delayed second dosing should be avoided in these patients, as vaccination after SARS-CoV-2 infection or a second dose leads to seroconversion in most individuals.

GUT (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis

Fatema Alrashed et al.

Summary: Corticosteroids and 5-ASA therapy for IBD were associated with an increased risk of severe COVID-19 outcomes, while anti-TNFs and ustekinumab were linked to favorable outcomes. Other IBD therapies like immunomodulators, tofacitinib, and vedolizumab did not show a significant association with severe disease.

BMJ OPEN GASTROENTEROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 A Prospective Cohort Study

Parakkal Deepak et al.

Summary: Patients with CID show immune response to mRNA-based SARS-CoV-2 vaccines, but some may have lower antibody levels, especially those receiving glucocorticoids and B-cell depletion therapy. Further studies are needed to confirm these preliminary findings.

ANNALS OF INTERNAL MEDICINE (2021)

添加到收藏夹

Letter Gastroenterology & Hepatology

BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign

Amir Ben-Tov et al.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications

Nabeel Khan et al.

Summary: The study found that full vaccination against SARS-CoV-2 has an effectiveness of approximately 80.4% in patients with inflammatory bowel disease who may be taking immunosuppressive medications.

GASTROENTEROLOGY (2021)

添加到收藏夹

Editorial Material Public, Environmental & Occupational Health

Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses

Laith J. Abu-Raddad et al.

JOURNAL OF TRAVEL MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

ANTI-SPIKE S1 IGA, ANTI-SPIKE TRIMERIC IGG, AND ANTI-SPIKE RBD IGG RESPONSE AFTER BNT162B2 COVID-19 MRNA VACCINATION IN HEALTHCARE WORKERS

Gian Luca Salvagno et al.

Summary: The study found that mRNA COVID-19 vaccination leads to sustained serum levels of anti-spike trimeric IgG and anti-spike RBD IgG, along with a modest but significant increase in anti-spike S1 IgA levels. Age was inversely associated with the overall increase of anti-spike trimeric IgG and anti-spike S1 IgA, but not with anti-spike RBD IgG levels.

JOURNAL OF MEDICAL BIOCHEMISTRY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology